Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Depreciation & Amortization (CF) (2018 - 2025)

Historic Depreciation & Amortization (CF) for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $29001.0.

  • BioNexus Gene Lab's Depreciation & Amortization (CF) fell 1537.0% to $29001.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $112992.0, marking a year-over-year increase of 1929.43%. This contributed to the annual value of $104160.0 for FY2024, which is 2511.26% up from last year.
  • As of Q3 2025, BioNexus Gene Lab's Depreciation & Amortization (CF) stood at $29001.0, which was down 1537.0% from $27800.0 recorded in Q2 2025.
  • BioNexus Gene Lab's Depreciation & Amortization (CF)'s 5-year high stood at $63129.0 during Q3 2023, with a 5-year trough of -$20879.0 in Q2 2023.
  • For the 5-year period, BioNexus Gene Lab's Depreciation & Amortization (CF) averaged around $23871.8, with its median value being $22636.0 (2022).
  • As far as peak fluctuations go, BioNexus Gene Lab's Depreciation & Amortization (CF) surged by 25467.39% in 2021, and later plummeted by 19223.8% in 2023.
  • Over the past 5 years, BioNexus Gene Lab's Depreciation & Amortization (CF) (Quarter) stood at $22794.0 in 2021, then rose by 8.88% to $24819.0 in 2022, then dropped by 18.99% to $20106.0 in 2023, then soared by 46.97% to $29549.0 in 2024, then decreased by 1.85% to $29001.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $29001.0 for Q3 2025, versus $27800.0 for Q2 2025 and $26642.0 for Q1 2025.